Tlr7 and tlr8 agonists for the treatment of cancer and/or infectious diseases
AssigneeThe Research Foundation for The State University of New York
InventorsLawrence Nathan TUMEY, Emmanuel OLAWODE
Life of this patent
Estimating the term…
Abstract
Disclosed herein are compounds of the Formula (I) or (II) or (III): Also disclosed are methods for stimulating an immune response, inducing an anti-tumor immune response, and treating an infectious disease in a subject by administering a therapeutically effective amount of a compound disclosed herein. Also disclosed are methods of treating a tumor or abnormal cell proliferation by administering a therapeutically effective amount of a compound disclosed herein under conditions effective to treat a tumor or abnormal cell proliferation.
Claims29
A compound of the Formula (I) or (II)
- wherein:
- R1 is selected from C1-C10 alkyl, C1-C10 oxaalkyl, and C1-C10 azaalkyl;
- R2 and R3 are each independently selected from hydrogen, C1-C5 alkyl, and C1-C5 alkoxy;
- n is 1 or 2
- Y is independently selected from optionally substituted aryl and optionally substituted heteroaryl;
- Z1 is selected from —NRZ—, —O—, —NRZC(O)—, —NRZC(O)—O—, and —NRZSO2—;
- Z2 is absent, or is selected from (C1-C8)hydrocarbon-NH— and a 5- to 8-membered nitrogen-containing heterocycle, wherein a nitrogen of the heterocycle is attached to X2;
- Z is independently selected from —NRZ—, —NRZC(O)—, and —O—;
- RZ is independently selected in each instance from hydrogen, C1-C8 hydrocarbon, C1-C8 oxaalkyl, C1-C8 azaalkyl, heteroaryl, and a 5- to 8-membered heterocyclic ring;
- X1 is independently selected from RZ, —C(O)—RZ, —C(O)—O—RZ, —C(O)—N—(RZ)2, —(CH2)kNRZC(O)—(C1-C6)alkyl, —(CH2)kNRZC(O)—O—(C1-C4)alkyl, and —SO2—RZ;
- k is an integer from 1 to 8;
- X2 comprises cleavable or noncleavable linker;
- and
- Ab comprises an antibody or an antibody fragment.
(canceled)
(canceled)
14-15. (canceled)
A compound of the Formula (III)
- wherein:
- R1 is selected from C1-C10 alkyl, C1-C10 oxaalkyl, and C1-C10 azaalkyl;
- R2 and R3 are each independently selected from hydrogen, C1-C5 alkyl, and C1-C5 alkoxy;
- n is 1 or 2;
- Y is selected from optionally substituted aryl and optionally substituted heteroaryl;
- ZA is selected from —NRZ—, —NRZC(O)—, —NRZC(O)—O—, —NRZC(O)—(CH2)k—NH—, —NRZC(O)—(CH2)k—O—, —C(O)—O—(CH2)k—O—, —NRZC(O)—(CH2)k—N(CH3)—, —NRZC(O)—O—(CH2)k—NH—, —NRZC(O)—(CH2)k—NH—C(O)—O—, and —NRZSO2—;
- k is an integer from 1 to 8;
- RZ is selected from hydrogen, C1-C8 hydrocarbon, C1-C8 oxaalkyl, C1-C8 azaalkyl, heteroaryl, and a 5- to 8-membered heterocyclic ring;
- and
- XA is selected from hydrogen, C1-C10 alkyl, and —C(O)CH3,
- wherein the following compound is excluded:
(canceled)
(canceled)
24-25. (canceled)
27-28. (canceled)
30-31. (canceled)
33-36. (canceled)
Dependencies are inferred from the claim text.